Adalimumab, etanercept, infliximab, and the risk of tuberculosis: Data from clinical trials, national registries, and postmarketing surveillance

Fabrizio Cantini, Laura Niccoli, Delia Goletti

Research output: Contribution to journalArticle

Fingerprint Dive into the research topics of 'Adalimumab, etanercept, infliximab, and the risk of tuberculosis: Data from clinical trials, national registries, and postmarketing surveillance'. Together they form a unique fingerprint.

Medicine & Life Sciences